Published in Hepatology on September 22, 2014
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet (2015) 2.17
Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology (2015) 1.65
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Targeting FGF19 binding to its receptor system: A novel therapeutic approach for hepatocellular carcinoma. Hepatology (2015) 1.06
Mediator kinase module and human tumorigenesis. Crit Rev Biochem Mol Biol (2015) 0.98
E-cadherin can limit the transforming properties of activating β-catenin mutations. EMBO J (2015) 0.94
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget (2016) 0.88
Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. Proc Natl Acad Sci U S A (2016) 0.87
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol (2015) 0.86
Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol (2016) 0.83
Serum DHCR24 Auto-antibody as a new Biomarker for Progression of Hepatitis C. EBioMedicine (2015) 0.83
Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J Hepatol (2015) 0.82
New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment. Hepatology (2014) 0.82
The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.82
FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation. Oncotarget (2016) 0.81
The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat Commun (2017) 0.80
Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. Int J Mol Sci (2017) 0.80
IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death Dis (2015) 0.79
Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. Genome Biol (2015) 0.79
Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. J Gastroenterol (2016) 0.78
Prognostic significance of Cbx4 expression and its beneficial effect for transarterial chemoembolization in hepatocellular carcinoma. Cell Death Dis (2015) 0.78
Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. Cancer Cell (2016) 0.77
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget (2016) 0.77
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun (2017) 0.76
Frequency and distribution of Notch mutations in tumor cell lines. BMC Cancer (2015) 0.76
Mutations of Chromatin Structure Regulating Genes in Human Malignancies. Curr Protein Pept Sci (2016) 0.76
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget (2017) 0.75
SIRT6 Depletion Suppresses Tumor Growth by Promoting Cellular Senescence Induced by DNA Damage in HCC. PLoS One (2016) 0.75
Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. Oncotarget (2016) 0.75
Prognostic significance of miR-1268a expression and its beneficial effects for post-operative adjuvant transarterial chemoembolization in hepatocellular carcinoma. Sci Rep (2016) 0.75
Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations. Oncotarget (2016) 0.75
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res (2016) 0.75
Rawcopy: Improved copy number analysis with Affymetrix arrays. Sci Rep (2016) 0.75
IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing. World J Surg Oncol (2017) 0.75
Transcriptome sequencing identified hub genes for hepatocellular carcinoma by weighted-gene co-expression analysis. Oncotarget (2016) 0.75
Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. Gastrointest Cancer (2015) 0.75
From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci (2017) 0.75
Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget (2016) 0.75
SRC-2-mediated coactivation of anti-tumorigenic target genes suppresses MYC-induced liver cancer. PLoS Genet (2017) 0.75
Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. Cancer Res (2017) 0.75
Reply. Hepatology (2015) 0.75
R-spondin 2 promotes proliferation and migration via the Wnt/β-catenin pathway in human hepatocellular carcinoma. Oncol Lett (2017) 0.75
Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer. Int J Biochem Cell Biol (2017) 0.75
Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases (2015) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Global variation in copy number in the human genome. Nature (2006) 57.50
Detection of large-scale variation in the human genome. Nat Genet (2004) 49.18
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell (2008) 28.29
Origins and functional impact of copy number variation in the human genome. Nature (2009) 23.63
Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science (2007) 23.38
Genetics of gene expression surveyed in maize, mouse and man. Nature (2003) 22.17
Signatures of mutational processes in human cancer. Nature (2013) 21.63
A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 20.65
International network of cancer genome projects. Nature (2010) 20.35
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63
Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet (2008) 15.89
Common deletion polymorphisms in the human genome. Nat Genet (2006) 15.66
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet (2010) 13.70
Mapping copy number variation by population-scale genome sequencing. Nature (2011) 12.55
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
EMBL Nucleotide Sequence Database in 2006. Nucleic Acids Res (2006) 9.72
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Copy number variation: new insights in genome diversity. Genome Res (2006) 8.66
Diet and the evolution of human amylase gene copy number variation. Nat Genet (2007) 8.64
The zebrafish reference genome sequence and its relationship to the human genome. Nature (2013) 8.52
Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell (2012) 8.41
Assemblathon 1: a competitive assessment of de novo short read assembly methods. Genome Res (2011) 8.38
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The first Korean genome sequence and analysis: full genome sequencing for a socio-ethnic group. Genome Res (2009) 7.87
Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods (2005) 7.87
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet (2009) 7.65
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev (2010) 7.14
Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell (2007) 7.05
Genome assembly comparison identifies structural variants in the human genome. Nat Genet (2006) 6.93
A highly annotated whole-genome sequence of a Korean individual. Nature (2009) 6.91
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
CTCF-mediated functional chromatin interactome in pluripotent cells. Nat Genet (2011) 6.55
Challenges and standards in integrating surveys of structural variation. Nat Genet (2007) 6.05
Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays. Genome Res (2006) 5.97
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol (2011) 5.57
Accurate and reliable high-throughput detection of copy number variation in the human genome. Genome Res (2006) 5.50
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A (2006) 5.27
Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell (2003) 5.26
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
EMBL Nucleotide Sequence Database: developments in 2005. Nucleic Acids Res (2006) 5.13
The fine-scale and complex architecture of human copy-number variation. Am J Hum Genet (2008) 5.08
Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). Genome Res (2007) 4.99
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med (2012) 4.90
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Multiplex sequencing of paired-end ditags (MS-PET): a strategy for the ultra-high-throughput analysis of transcriptomes and genomes. Nucleic Acids Res (2006) 4.51
Completing the map of human genetic variation. Nature (2007) 4.38
Landscape of somatic retrotransposition in human cancers. Science (2012) 4.37
Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell (2002) 4.29
Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics (2004) 4.09
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Exploiting indirect neighbours and topological weight to predict protein function from protein-protein interactions. Bioinformatics (2006) 3.94
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nat Biotechnol (2006) 3.68
Hotspots for copy number variation in chimpanzees and humans. Proc Natl Acad Sci U S A (2006) 3.68
Mutation spectrum revealed by breakpoint sequencing of human germline CNVs. Nat Genet (2010) 3.52
Discovery of common Asian copy number variants using integrated high-resolution array CGH and massively parallel DNA sequencing. Nat Genet (2010) 3.49
A p53-dependent checkpoint pathway prevents rereplication. Mol Cell (2003) 3.42
Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat Biotechnol (2011) 3.25
ChIA-PET tool for comprehensive chromatin interaction analysis with paired-end tag sequencing. Genome Biol (2010) 3.24
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology (2006) 3.02
Opera: reconstructing optimal genomic scaffolds with high-throughput paired-end sequences. J Comput Biol (2011) 2.85
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85
An HMM approach to genome-wide identification of differential histone modification sites from ChIP-seq data. Bioinformatics (2008) 2.85
Temporal profile of replication of human chromosomes. Proc Natl Acad Sci U S A (2005) 2.85
Towards a comprehensive structural variation map of an individual human genome. Genome Biol (2010) 2.79
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
Extensive genomic and transcriptional diversity identified through massively parallel DNA and RNA sequencing of eighteen Korean individuals. Nat Genet (2011) 2.74
Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J (2009) 2.72
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol (2006) 2.69
Copy number variation and evolution in humans and chimpanzees. Genome Res (2008) 2.69
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (2014) 2.68
Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. Hum Pathol (2007) 2.67
A signal-noise model for significance analysis of ChIP-seq with negative control. Bioinformatics (2010) 2.66
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res (2005) 2.65
Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys (2008) 2.59
Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet (2008) 2.58
Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl (2006) 2.58
Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol (2009) 2.51
Complex reorganization and predominant non-homologous repair following chromosomal breakage in karyotypically balanced germline rearrangements and transgenic integration. Nat Genet (2012) 2.45